dexmethylphenidate tablet / Generic mfg. - LARVOL DELTA

Consecutive double chiral-switches strategy. ADHD methylphenidate drugs: from two racemates via racemate to enantiomer. (PubMed, Future Med Chem) - "The notations of the active ingredients of Ritalin (methylphenidate hydrochloride) and of Focalin (dexmethylphenidate hydrochloride) are stereochemically flawed and the designations of the stereodescriptors of relative configurations erythro and threo are obsolete. The Perspective calls for correct notations of methylphenidate drugs and for future applications of the double chiral-switches strategy."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Drugs for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - P4 | N=10 | Recruiting | Sponsor: Matthew J O'Brien, PhD, BCBA-D | Trial completion date: Jan 2025 ➔ Aug 2027 | Trial primary completion date: Jan 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Psychiatry

"These include brand name (= Generic version): - @VYVANSE (Lisdexamfetamine) - Concerta, Ritalin LA, Daytrana, etc (Methylphenidate) - Focalin ER (Dexmethylphenidate ER) @Novartis - Adderall XR - Dexedrine, etc (Dextroamphetamine) - Azstarys These last 12 hours or longer" (@RTorof)

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD (clinicaltrials.gov) - P=N/A | N=70 | Completed | Sponsor: Nemours Children's Clinic | Recruiting ➔ Completed | N=50 ➔ 70 | Trial completion date: Jun 2021 ➔ Jun 2022 | Trial primary completion date: Jun 2021 ➔ Jun 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

In brief: Alternatives to Adderall. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Transcriptomic Profiling Reveals Underlying Immunoregulation Mechanisms of Resistant Hypertension in Injection Drug Users. (PubMed, J Inflamm Res) - "Functional analysis demonstrated that pathways of focal adhesion and focalin-1-rich granule lumen were involved in the development of IDU-DR, and the cytosolic large ribosomal subunit may relate to IDU-DR...The abundance of cytotoxic T cells (Tc) was significantly different between IDU-DS and IDU-DR. Our findings indicated a potential function of immunoregulation mechanisms for resistant hypertension."

Journal • Cardiovascular • Hypertension • CD8

Palladium-Catalyzed Enantioselective C(sp)-H/C(sp)-H Umpolung Coupling of N-Allylimine and α-Aryl Ketones. (PubMed, J Am Chem Soc) - "A wide variety of α-heteroaryl ketones and 2-acylimidazoles are nicely tolerated to open a convenient and tunable avenue for efficient synthesis of enantioenriched β-amino-γ,δ-unsaturated carbonyl derivatives with high levels of regio- and stereoselectivities, capable of providing a key intermediate for asymmetric synthesis of Focalin. This protocol showcases an umpolung reactivity of the N-allylimines through a concerted proton and two-electron transfer process to cleave the allylic C-H bond, effectively complementing established methodology for allylic C-H functionalization. An inner-sphere allylation pathway for both α-heteroaryl carbonyls and 2-acylimidazoles to attack the π-allylpalladium species is suggested by computational studies and experimental facts, wherein the nitrogen coordination to the palladium center enables the preference of branched regioselectivity."

Journal

Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

[VIRTUAL] Poor prognostic factors of papillary thyroid microcarcinomas (ECP 2021) - "The remaining 14 patients received multipledosesofRAItherapy forrecurrencesorothercauses.Thetumourwas bilateralin29 patients(50%)and multifocalin36 patients(62%).Microscopic extrathyroidal extension (ETE) was detected in 32 patients (55.2%)... Although a very good prognosis is mostly observed in pap- illary microcarcinoma, it should be kept in mind that some clinical and histomorphological features may cause poor clinical course."

Biomarker • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma

"Bifocaling? 😂" (@NTrikalinos)

Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - P4; N=10; Recruiting; Sponsor: Matthew J O'Brien, PhD, BCBA-D; Trial completion date: Jan 2021 ➔ Jan 2025; Trial primary completion date: Jan 2021 ➔ Jan 2025

Clinical • Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Psychiatry

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD (clinicaltrials.gov) - P; N=50; Recruiting; Sponsor: Nemours Children's Clinic

New trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

[VIRTUAL] Comparative Bioavailability and Safety of a Novel Trimodal Dexmethylphenidate Tablet in ADHD Patients (AACAP 2020) - No abstract available

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - P=N/A; N=10; Not yet recruiting; Sponsor: Matthew O'Brien

New trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Biosimilar • CNS Disorders

Cingulate Therapeutics to present new data from its first in human proof of concept trial of CTX-1301 at the 2018 APSARD Annual Meeting (PRNewswire) - "Cingulate Therapeutics...announced the acceptance of data from its proof of concept clinical trial of CTX-1301 for poster presentation at the 2018 APSARD Annual Meeting...The presentation will mark the final release of data from a study conducted in 2017 evaluating CTX-1301, Cingulate's proprietary, first-line stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder..."

PK/PD data • Attention Deficit Hyperactivity Disorder • CNS Disorders

CTx-1301 Comparative Bioavailability Study (clinicaltrials.gov) - P1/2; N=45; Completed; Sponsor: Cingulate Therapeutics; Recruiting ➔ Completed

Clinical • Trial completion

"@Novartis focalin" (@DamienGallego11)

Drugs for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Review

When to Raise Our White Flag-A Discussion of Scope of Practice in a Resource Scarce World. (PubMed, J Dev Behav Pediatr) - "His mother describes an increase in symptoms of anxiety and depression for the last 6 weeks, accompanied by suicidal ideation and thoughts of self-mutilation.Before this increase in symptoms, he had been doing well for the last several months with the exception of increasing weight gain, and Abilify was decreased from 5 mg to 2.5 mg at his last visit. Other medications at that time included Zoloft 100 mg twice daily, Focalin XR 40 mg every morning, and Focalin 5 mg every night...He was evaluated by BHS, diagnosed with anxiety disorder, and started on Lexapro...Medications were adjusted with input from BHS, and further attempts were made to link him to local BHS but were unsuccessful. With his current concerns of suicidal ideation and self-mutilation, what would be your next steps?"

Journal

Effects of Dexmethylphenidate on Targeted and Non-Targeted Behaviours during Functional Analyses: A Brief Report. (PubMed, Dev Neurorehabil) - "These findings provide further support that stimulant medication may change the function of disruptive behavior and highlight the need to investigate the effects of stimulants on non-targeted behaviors."

Journal

CTx-1301 Comparative Bioavailability Study (clinicaltrials.gov) - P1/2; N=36; Recruiting; Sponsor: Cingulate Therapeutics; Not yet recruiting ➔ Recruiting

Enrollment open

Jornay PM -- evening-dosed methylphenidate for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available.

Journal

CTx-1301 Comparative Bioavailability Study (clinicaltrials.gov) - P1/2; N=36; Not yet recruiting; Sponsor: Cingulate Therapeutics

Clinical • New P1/2 trial

"@TevaUSA quit manufacturing the generic of focalin. Nothing like not being able to get your preferred generic." (@MMWesterfeld)